All those infected belong to the same family from San Javier, Rio Negro Department, who recently traveled to Bolivia.
The Ministry is investigating five other suspected cases in the rural area of the same town.
Two days ago, the…

All those infected belong to the same family from San Javier, Rio Negro Department, who recently traveled to Bolivia.
The Ministry is investigating five other suspected cases in the rural area of the same town.
Two days ago, the…

Data from a china clay mining company is to be reviewed by the Environment Agency after a stream near Truro turned milky white.
The stream in Coombe is a contributory to the River Fal and after heavy rainfall on Friday turned from brown to white…

In late November and early December 2025, Deutsche Bank Aktiengesellschaft issued and announced multiple fixed‑coupon, senior unsecured, callable notes across maturities from 2029 to 2050, including several Eurobond and Eurodollar formats priced at par with discounts of 0.4% to 5% per security.
This burst of fixed‑income issuance highlights Deutsche Bank’s active use of debt markets to refine its funding profile and support its broader banking activities, coinciding with a senior hire to lead global private bank investment solutions.
We will now examine how this wave of senior unsecured bond issuance might influence Deutsche Bank’s investment narrative and future earnings mix.
These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.
To own Deutsche Bank, you need to believe it can convert improving profitability and disciplined capital returns into durable earnings, despite low forecast growth and lingering asset quality and litigation risks. The recent wave of fixed coupon senior unsecured issuance modestly tightens the funding story but does not materially change the near term focus on credit costs, especially in U.S. CRE, or on managing large one off items that still cloud earnings quality.
Among recent announcements, the appointment of Vivienne Chia as global head of private bank investment solutions stands out as most connected to this funding activity, because it speaks to the mix of fee based and interest driven earnings these bonds may support over time. As the private bank builds out higher margin investment solutions on top of a still credit heavy balance sheet, the key question is how quickly that mix can offset pressures from regulation, competition and capital requirements.
Yet investors should be aware that rising regulatory complexity and capital requirements could still…
Read the full narrative on Deutsche Bank (it’s free!)
Deutsche Bank’s narrative projects €33.8 billion revenue and €6.8 billion earnings by 2028. This requires 4.0% yearly revenue growth and about a €1.3 billion earnings increase from €5.5 billion today.
Uncover how Deutsche Bank’s forecasts yield a €31.30 fair value, in line with its current price.
Seven fair value estimates from the Simply Wall St Community span roughly €17 to about €35.89 per share, underlining how far apart views on Deutsche Bank’s upside can sit. When you weigh those opinions against the risk of persistently elevated credit losses and high bad loans, it becomes even more important to compare several viewpoints before deciding how this bank might fit into your portfolio.

Netflix Inc.’s $72 billion acquisition of Warner Bros. Discovery Inc. includes one of the biggest breakup fees of all time — a $5.8 billion penalty that Netflix has agreed to pay its target if the deal falls apart or fails to win regulatory…

Prothena’s fair value estimate has been nudged higher from $18.33 to $20.33 per share as analysts grow more confident in the company’s partnered pipeline and its potential to drive stronger long term revenue. The model now assumes faster top line expansion, with projected revenue growth raised from 74.7% to 90.9%, reflecting optimism around milestones, royalties, and expanding indications. Read on to see how this evolving narrative is reshaping expectations for Prothena and how you can stay aligned with future updates.
Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Prothena.
🐂 Bullish Takeaways
Piper Sandler reaffirmed its Overweight rating and more than doubled its price target on Prothena to $36 from $15, signaling increased conviction in the stock’s upside relative to current levels.
The firm highlights the value of Prothena’s partnered pipeline, pointing to potential income from net sales royalties and milestone payments as a key driver of long term growth momentum.
Piper Sandler describes the next 12+ months as catalyst rich, indicating confidence in Prothena’s execution on upcoming milestones and its ability to sustain revenue expansion that supports the higher valuation framework.
🐻 Bearish Takeaways
Even as Piper Sandler turns more positive on upside potential, the reliance on future milestones and royalties underscores ongoing execution and timing risks that could challenge the durability of the current valuation if key catalysts slip or underperform.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
Presented new preclinical data on CYTOPE, a novel drug delivery modality for cytosolic delivery of macromolecules to the brain and periphery, at Neuroscience 2025, highlighting its potential to target previously undruggable intracellular disease pathways.
Reported preclinical ALS results showing that systemically administered TDP 43 CYTOPE reached the brain, localized to intracellular pTDP 43 pathology, and significantly reduced pTDP 43 aggregates and associated RNA dysregulation in mouse models and human neuronal systems.
Announced publication of Phase 2 data for coramitug, a potential first in class amyloid depleter antibody for ATTR cardiomyopathy, in Circulation, with the results highlighted in a late breaking session at AHA Scientific Sessions 2025 and supporting its late stage cardiovascular franchise.
Highlighted advancement of coramitug into the Phase 3 CLEOPATTRA trial led by Novo Nordisk, under a collaboration that could deliver up to $1.2 billion in milestones for Prothena, including additional clinical milestone payments tied to enrollment targets.

James Vowles, Team Principal: First of all, congratulations to Max. Really impressive laps out there and he was dominant through sector 3. Speaking of which, that was the sector we couldn’t quite get right today. The gaps were miniscule. Just a…


If you’ve ever gone from one kiss to pants half off and thought, “Wait, I’m not ready yet,” Violet Benson and Dr. Emily Morse are talking directly to you. On Almost Adulting, the Sex With Emily host walks through why…

Max Verstappen could not hide his delight and satisfaction after producing another spectacular Qualifying display to bag pole position for the Abu Dhabi Grand Prix.
Verstappen had trailed championship leader Lando Norris in all three practice…

Eye surgery is one of the most persistent health challenges, specifically cataract surgery. USLA researchers helped make this challenging operation a little “simpler” for surgeons.
Researchers and surgeons completed the world’s…